Analyze Diet

Gene-based vaccines: Recent developments.

Abstract: Gene-based vaccines are under development for a broad variety of applications, ranging from vaccines to immunotherapies for infectious diseases, cancer, autoimmune diseases and allergy. In addition, following the licensing of DNA vaccines for use in fish and horses, and DNA immunotherapy for the treatment of cancer in dogs, several veterinary uses of vaccines have been demonstrated for species ranging from fish and shrimp to cattle and horses. A variety of publications describing preclinical and clinical studies of the technologies used to increase the potency of gene-based vaccines, and research further elucidating the immune mechanisms involved have recently become available. This review discusses the progress and observations described in the recent literature, including a survey of the diseases and approaches that are being targeted with gene-based vaccines.
Publication Date: 2010-02-09 PubMed ID: 20140820
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article reviews the latest developments in the production and application of gene-based vaccines. These vaccines are being explored for a wide range of uses, from preventative measures against infectious diseases to treatments for cancer, autoimmune diseases, and allergies.

Research on Gene-Based Vaccines

The body of the research discusses the advancements in the field of gene-based vaccines. Gene-based vaccines are innovative topic in immunology, with wide-ranging applications. The researchers reviewed multiple studies and gathered significant information on:

  • The various applications of gene-based vaccines, including as vaccines and immunotherapies for infectious diseases, cancer, autoimmune diseases, and allergies.
  • The potential veterinary uses for these vaccines. After the licensing of DNA vaccines for use in fish and horses, as well as for cancer treatment in dogs, the field has expanded. These vaccines have shown promise in a variety of animal species, including not just fish and horses, but also shrimp and cattle.
  • The technology used to increase the efficacy of these gene-based vaccines. This includes various methods of delivery and formulation improvements meant to enhance the immune response and increase the vaccine’s potency.
  • Studies that further explore immune mechanisms, shedding light on how these vaccines interact with the immune system and the unique immune responses they elicit.

Diseases and Approaches Targeted by Gene-Based Vaccines

Further, the article discusses the diseases that these vaccines are designed to tackle and the approaches used to create them.

  • Gene-based vaccines can potentially revolutionize the way we prevent and treat a wide range of diseases. From traditional applications like vaccination against infectious diseases, to novel treatments for autoimmune diseases, cancer, and allergies, gene-based vaccines can have broad utilities.
  • Research includes exploration of genetic manipulation and DNA recombination techniques to develop potent vaccines. The vaccines work by introducing into the body a modified form of a disease’s gene, provoking the immune system to recognize and fight off the disease should it ever encounter it.
  • Developments are not limited to humans. Several veterinary vaccines have been tested on a variety of species, highlighting the potential for cross-species benefits of gene-based therapies.

The article concludes with a review of recent literature in the field and discusses future avenues for research and development. This includes further understanding of the immune mechanisms involved and continued expansion of diseases targetable by gene-based vaccines.

Cite This Article

APA
Liu MA. (2010). Gene-based vaccines: Recent developments. Curr Opin Mol Ther, 12(1), 86-93.

Publication

ISSN: 2040-3445
NlmUniqueID: 100891485
Country: England
Language: English
Volume: 12
Issue: 1
Pages: 86-93

Researcher Affiliations

Liu, Margaret A
  • ProTherImmune, Lafayette, CA 94549, USA. liu@protherimmune.com

MeSH Terms

  • Animals
  • Clinical Trials as Topic
  • Genetic Vectors / genetics
  • Genetic Vectors / immunology
  • Humans
  • Immunity, Innate / immunology
  • Vaccines, DNA / genetics
  • Vaccines, DNA / immunology
  • Vaccines, DNA / therapeutic use

Citations

This article has been cited 9 times.
  1. Morante V, Borghi M, Farina I, Michelini Z, Grasso F, Gallinaro A, Cecchetti S, Di Virgilio A, Canitano A, Pirillo MF, Bona R, Cara A, Negri D. Integrase-Defective Lentiviral Vector Is an Efficient Vaccine Platform for Cancer Immunotherapy. Viruses 2021 Feb 23;13(2).
    doi: 10.3390/v13020355pubmed: 33672349google scholar: lookup
  2. Isakova-Sivak I, Matyushenko V, Stepanova E, Matushkina A, Kotomina T, Mezhenskaya D, Prokopenko P, Kudryavtsev I, Kopeykin P, Sivak K, Rudenko L. Recombinant Live Attenuated Influenza Vaccine Viruses Carrying Conserved T-cell Epitopes of Human Adenoviruses Induce Functional Cytotoxic T-Cell Responses and Protect Mice against Both Infections. Vaccines (Basel) 2020 Apr 24;8(2).
    doi: 10.3390/vaccines8020196pubmed: 32344618google scholar: lookup
  3. Lin YY, Belle I, Blasi M, Huang MN, Buckley AF, Rountree W, Klotman ME, Cara A, Negri D. Skeletal Muscle Is an Antigen Reservoir in Integrase-Defective Lentiviral Vector-Induced Long-Term Immunity. Mol Ther Methods Clin Dev 2020 Jun 12;17:532-544.
    doi: 10.1016/j.omtm.2020.03.008pubmed: 32258216google scholar: lookup
  4. Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, Patterson N, Guerrero M, Bennett JW, McGrath S, Ganeshan H, Belmonte M, Farooq F, Abot E, Banania JG, Huang J, Newcomer R, Rein L, Litilit D, Richie NO, Wood C, Murphy J, Sauerwein R, Hermsen CC, McCoy AJ, Kamau E, Cummings J, Komisar J, Sutamihardja A, Shi M, Epstein JE, Maiolatesi S, Tosh D, Limbach K, Angov E, Bergmann-Leitner E, Bruder JT, Doolan DL, King CR, Carucci D, Dutta S, Soisson L, Diggs C, Hollingdale MR, Ockenhouse CF, Richie TL. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 2013;8(2):e55571.
    doi: 10.1371/journal.pone.0055571pubmed: 23457473google scholar: lookup
  5. Babaie J, Sadeghiani G, Golkar M. Construction and In vitro Expression Analyses of a DNA Plasmid Encoding Dense Granule GRA5 Antigen of Toxoplasma gondii. Avicenna J Med Biotechnol 2011 Jul;3(3):135-41.
    pubmed: 23407179
  6. Chen H, Chuai X, Deng Y, Wen B, Wang W, Xiong S, Ruan L, Tan W. Optimisation of prime-boost immunization in mice using novel protein-based and recombinant vaccinia (Tiantan)-based HBV vaccine. PLoS One 2012;7(9):e43730.
    doi: 10.1371/journal.pone.0043730pubmed: 22970140google scholar: lookup
  7. Bot A, Qiu Z, Wong R, Obrocea M, Smith KA. Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity. J Transl Med 2010 Dec 14;8:132.
    doi: 10.1186/1479-5876-8-132pubmed: 21144062google scholar: lookup
  8. Zhang Q, Ma Q, Li Q, Yao W, Wang C. Enhanced protection against nasopharyngeal carriage of Streptococcus pneumoniae elicited by oral multiantigen DNA vaccines delivered in attenuated Salmonella typhimurium. Mol Biol Rep 2011 Feb;38(2):1209-17.
    doi: 10.1007/s11033-010-0219-7pubmed: 20563651google scholar: lookup
  9. Lin CC, Yu YL, Shih CC, Liu KJ, Ou KL, Hong LZ, Chen JD, Chu CL. A novel adjuvant Ling Zhi-8 enhances the efficacy of DNA cancer vaccine by activating dendritic cells. Cancer Immunol Immunother 2011 Jul;60(7):1019-27.
    doi: 10.1007/s00262-011-1016-4pubmed: 21499904google scholar: lookup